Nicox Presents Phase 3 Data of NCX 470 at the American Glaucoma Society
Nicox announces the presentation of its Phase 3 study results on NCX 470 at the 2026 annual meeting of the American Glaucoma Society, scheduled from February 19 to 22, 2026 in California. Two oral podium presentations are planned, alongside a poster presentation.
Detailed Presentation Schedule
The ophthalmic company Nicox will present data from its Phase 3 studies on NCX 470, a nitric oxide-donating bimatoprost eye drop aimed at reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Three presentations are scheduled at the American Glaucoma Society (AGS) congress: two oral podium presentations on Friday, February 20, 2026, and one poster presentation on the same day. The first oral presentation, titled 'A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial', will be presented at 10:15 AM by Dr. S. Asrani from Duke University Medical Center. The second presentation, 'Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial', will be presented at 10:25 AM by Dr. A. Sit from the Mayo Clinic. A third poster presentation will focus on the results from the American subgroup of the DENALI trial.
Regulatory Submissions and Collaborations
This presentation occurs at a time when Nicox is preparing regulatory submissions for NCX 470 in the United States and China with its licensed partners, Kowa and Ocumension Therapeutics respectively. NCX 470 is the company's main program in advanced development phase. Additionally, Nicox is conducting a preclinical research program, NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, in collaboration with Glaukos. Members of the Nicox team will participate in individual meetings during the congress.
